Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks

Schizophrenia Research

Volumn 95, Issue 1-3, 2007, Pages 143-150

  Kane, John M ^a   Crandall, David T ^b   Marcus, Ronald N ^b   Eudicone, James ^b   Pikalov III, Andrei ^c   Carson, William H ^d   Swyzen, Wim ^b  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c Otsuka America Pharmaceutical   (United States)

^d OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Aripiprazole; Haloperidol; Schizophrenia; Symptomatic remission

Indexed keywords

ARIPIPRAZOLE; HALOPERIDOL;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCHIZOPHRENIA; UNSPECIFIED SIDE EFFECT;

ACUTE DISEASE; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; DOUBLE-BLIND METHOD; HALOPERIDOL; HUMANS; LONGITUDINAL STUDIES; PIPERAZINES; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; RESEARCH DESIGN; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 34548189418     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2007.05.009     Document Type: Article

References (28)

1. Andreasen N.C., Carpenter Jr. W.T., Kane J.M., et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry 162 (2005) 441-449
2. Arato M., O'Connor R., Meltzer H.Y., and ZEUS Study Group. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80, and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int. Clin. Psychopharmacol. 17 (2002) 207-215
3. Ayuso-Gutiérrez J.L., and del Rio Vega J. Factors influencing relapse in the long-term course of schizophrenia. Schizophr. Res. 28 (1997) 199-206
4. Beasley Jr. C.M., Sutton V.K., Hamilton S.H., et al. Olanzapine relapse prevention study group. A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. J. Clin. Psychopharmacol. 23 (2003) 582-594
5. Burris K.D., Molski T.F., and Xu C. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther. 302 (2002) 381-389
6. Casey D.E. Barriers to progress-the impact of tolerability problems. Int. Clin. Psychopharmacol. 16 Suppl 1 (2001) S15-S19
7. Clark, W., Stock, E., Marder, S., et al., 2003. Safety and tolerability meta-analysis of aripiprazole in schizophrenia. Presented at: International Society of Psychiatric-Mental Health Nurses Meeting. April 23-26, 2003, Charleston, SC.
8. Csernansky J.G., Mahmoud R., and Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N. Engl. J. Med. 346 (2002) 16-22
9. Dossenbach M., Arango-Davila C., Silva Ibarra H., et al. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. J. Clin. Psychiatry 66 (2005) 1021-1030
10. Haro J.P., Novick D., Suarez D., et al. Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes Study (SOHO). J. Clin. Psychopharmacol. 26 (2006) 571-578
11. Herz M.I., Lamberti J.S., Mintz J., et al. A program for relapse prevention in schizophrenia: a controlled study. Arch. Gen. Psychiatry 57 (2000) 277-283
12. Hirose T., Uwahodo Y., Yamada S., et al. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J. Psychopharmacol. 18 (2004) 375-383
13. Jordan S., Koprivica V., Chen R., et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur. J. Pharmacol. 441 (2002) 137-140
14. Kane J. Olanzapine in the long-term treatment of schizophrenia. Br. J. Psychiatry 37 (1999) 26-29
15. Kane J.M. Commentary on the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). J. Clin. Psychiatry 67 (2006) 831-832
16. Kasper S., Brecher M., Fitton L., and Jones M. Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia. Int. Clin. Psychopharmacol. 19 (2004) 363
17. Kasper S., Lerman M.N., McQuade R.D., et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int. J. Neuropsychopharmacol. 6 (2003) 325-337
18. Lambert M., Schimmelmann B.G., Naber D., et al. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J. Clin. Psychiatry 67 (2006) 1690-1697
19. Lasser R.A., Bossie C.A., Gharabawi G.M., et al. Remission in schizophrenia: results from a 1-year study of long-acting risperidone injection. Schizophr. Res. 77 (2005) 215-227
20. Marder S.R., McQuade R.D., Stock E., et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr. Res. 61 (2003) 123-136
21. McQuade R.D., Burris K.D., Jordan S., et al. Aripiprazole: a dopamine-serotonin system stabilizer. Int. J. Neuropsychopharmacol. 5 Suppl 1 (2002) S176
22. Novick D., Haro J.M., Suarez D., Lambert M., et al. Symptomatic remission in previously untreated patients with schizophrenia: 2-year results from the SOHO study. Psychopharmacology 191 (2007) 1015-1022
23. Pigott T.A., Carson W.H., Saha A.R., et al., Aripiprazole Study Group. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J. Clin. Psychiatry 64 (2003) 1048-1056
24. Schooler N., Rabinowitz J., Davidson M., et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am. J. Psychiatry 162 (2005) 947-953
25. Shapiro D.A., Renock S., Arrington E., et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28 (2003) 1400-1411 (Epub May 21, 2003)
26. Tandon R., Marcus R.N., Stock E.G., et al. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). Schizophr. Res. 84 (2006) 77-89
27. Tran P.V., Delva M.A., Tollefson G.D., et al. Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br. J. Psychiatry 172 (1998) 499-505
28. Wyatt R.J. Neuroleptics and the natural course of schizophrenia. Schizophr. Bull. 17 (1991) 325-351